Elevated asymmetric dimethylarginine is associated with oxidant Stress Aggravation in patients with early stage autosomal dominant polycystic Kidney Disease

Kidney and Blood Pressure Research

Volumn 38, Issue 1, 2014, Pages 72-82

  Raptis, Vassilios ^a   Georgianos, Panagiotis I ^a   Sarafidis, Pantelis A ^a   Sioulis, Athanasios ^a   Makedou, Kali ^b   Makedou, Areti ^c   Grekas, Dimitrios M ^a   Kapoulas, Stergios ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Laboratory for Lipids and Cardiovascular Disease Prevention 2nd Pediatric Department   (Greece)

Author keywords

ADMA; ADPKD; Asymmetric dimethylarginine; autosomal dominated polycystic kidney disease; eGFR; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; 15-F2T-ISOPROSTANE; ARGININE; LOW DENSITY LIPOPROTEIN; N,N-DIMETHYLARGININE;

ADULT; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; MALE; OXIDATIVE STRESS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; AGED; GLOMERULUS FILTRATION RATE; PATHOGENESIS; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; DISEASE COURSE; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ARGININE; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; ISOPROSTANES; KIDNEY FUNCTION TESTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; YOUNG ADULT;

EID: 84895649049     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000355756     Document Type: Article

References (34)

1. Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009;76:149-168.
2. Grantham JJ, Chapman AB, Torres VE: Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006;1:148-157.
3. Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP: Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007;2:112-120.
4. Wang D, Iversen J, Strandgaard S: Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats. J Vasc Res 1999;36:502-509.
5. Wang D, Braendstrup O, Larsen S, Horn T, Strandgaard S: The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS 2004;112:358-368.
6. Borresen ML, Wang D, Strandgaard S: Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am J Nephrol 2007;27:240-246.
7. Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, Alisir S, Turgut F, Mercanoglu F, Ecder T: Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004;43:854-860.
8. Raptis V, Kapoulas S, Grekas D: Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology (Carlton) 2013;18:11-21.
9. Schwedhelm E, Boger RH: The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol 2011;7:275-285.
10. Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-176.
11. Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS: Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008;51:184-191.
12. Karamouzis I, Sarafidis PA, Karamouzis M, Iliadis S, Haidich AB, Sioulis A, Triantos A, Vavatsi-Christaki N, Grekas DM: Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol 2008;28:397-404.
13. Wilcox CS: Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005;289:R913-R935.
14. Maser RL, Vassmer D, Magenheimer BS, Calvet JP: Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease. J Am Soc Nephrol 2002;13:991-999.
15. Torres VE, Bengal RJ, Litwiller RD, Wilson DM: Aggravation of polycystic kidney disease in Han:SPRD rats by buthionine sulfoximine. J Am Soc Nephrol 1997;8:1283-1291.
16. Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M: Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:7-13.
17. Milne GL, Morrow JD: Isoprostanes and related compounds: update 2006. Antiox Redox Signal 2006;8:1379-1384.
18. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
19. Schwedhelm E: Quantification of ADMA: analytical approaches. Vasc Med 2005;10:S89-S95.
20. Wang D, Iversen J, Strandgaard S: Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000;11:1371-1376.
21. Wang D, Iversen J, Wilcox CS, Strandgaard S: Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003;64:1381-1388.
22. Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V: Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2011;26:2515-2521.
23. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C: ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006;70:781-787.
24. Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J: ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 2008;19:388-395.
25. Iakoubova OA, Dushkin H, Beier DR: Genetic analysis of a quantitative trait in a mouse model of polycystic kidney disease. Am J Respir Crit Care Med 1997;156:S72-S77.
26. Mizuno Y, Jacob RF, Mason RP: Inflammation and the development of atherosclerosis. J Atheroscler Thromb 2011;18:351-358.
27. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP: Lipid lowering agents and the endothelium: an update after 4 years. Curr Vasc Pharmacol 2012;10:33-41.
28. Leiper J, Murray-Rust J, McDonald N, Vallance P: S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002;99:13527-13532.
29. Vallance P, Leiper J: Blocking NO synthesis: how, where and why? Nat Rev Drug Discov 2002;1:939-950.
30. Brookes ZL, Ruff L, Upadhyay VS, Huang L, Prasad S, Solanky T, Nauli SM, Ong AC: Pkd2 mesenteric vessels exhibit a primary defect in endothelium- dependent vasodilatation restored by rosiglitazone. Am J Physiol Heart Circ Physiol 2013;304:H33-H41.
31. Mihout F, Shweke N, Bigé N, Jouanneau C, Dussaule JC, Ronco P, Chatziantoniou C, Boffa JJ: Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis. J Pathol 2011;223:37-45.
32. Ueda S, Yamagishi S, Matsumoto Y, Kaida Y, Fujimi-Hayashida A, Koike K, Tanaka H, Fukami K, Okuda S: Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD). Life Sci 2009;84:853-856.
33. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-2461.
34. Hanai K, Babazono T, Nyumura I, Toya K, Tanaka N, Tanaka M, Ishii A, Iwamoto Y: Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 2009;24:1884-1888.